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Fetal and early postnatal life represent critical periods in vertebrate immune system development.
Disruption of such development by perinatal immunotoxic chemical exposure has been widely
described in experimental animal models. The resultant inhibited postnatal immune responses in
such animals are often more dramatic and persistent than those after exposure during adult life.
Further, recent reports suggest that prenatal exposure to immunotoxicants may exacerbate
postnatal aberrant immune responses (e.g., hypersensitivity disorders and autoimmune disease) in
genetically predisposed rodents. Limited information is available regarding the possibility of inhibited
postnatal immune capacity in humans as a result of developmental immunotoxicant exposure. The
multifactorial nature of hypersensitivity and autoimmune responses will further complicate the
elucidation of possible relationships between chemical exposure during ontogeny of the human
immune system and immune-mediated disease later in life. Taken together, however, the available
animal data suggest the potential for altered postnatal immune function in humans exposed to
immunotoxicants (e.g., environmental chemicals and therapeutic agents) during fetal and/or early
postnatal life. Key words: autoimmune disease, developmental immunotoxicity, diethylstilbestrol,
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Establishment of the vertebrate immune
system requires a sequential series ofcarefully
timed and coordinated developmental events
that begin early in embryonic/fetal life and
continue through the early postnatal period.
Perturbation or abrogation of this develop-
mental sequence of events can lead to
immune dysfunctions that may be life threat-
ening. Defects in the development of the
immune system due to heritable changes in
the lymphoid elements provide clinical and
experimental examples ofthe devastating con-
sequences ofimpaired immune development.
Potential functional defects caused by
exposure to toxic agents during development
may range from life-threatening suppression
ofvital components ofthe immune system to
altered or poorly regulated responses that can
be debilitating. For example, studies in labo-
ratory rodents indicate that exposure to
immunotoxicants (e.g., environmental chemi-
cals, drugs, and ionizing radiation) during
this critical time of immune system develop-
ment may produce persistent, and in some
cases dramatic, effects on postnatal immune
function. For certain chemical agents {e.g.,
chlordane; benzo[a]pyrene (B[a]P); and
2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD)}, perinatal exposure has been associ-
ated with what appears to be lifelong
immunosuppression. For some of the same
and other chemical agents (e.g., therapeutic
or environmental estrogens and TCDD),
there is evidence that exposure early in life
may exacerbate or induce autoimmune
responses ingeneticallypredisposed individuals.
The full extent of the immunological effects
resulting from exposure to environmental
agents during immune system development is
not yet known; however, the potential for
serious consequences is obvious.
Developmental immunotoxicology as a
discipline is in its infancy, with much remain-
ing to be learned. Indeed, limited human
data are available regarding the spectrum of
potential postnatal immune consequences
that may result from gestational and/or early
postnatal exposure to individual or mixtures
ofimmunotoxic compounds. We describe the
development of the immune system and
compare the similarities and differences of
this development in humans and laboratory
animals; review the evidence that the develop-
ing immune system is sensitive to perturba-
tion by chemical and physical agents and that
consequent agent-induced immune dysfunc-
tion may continue through life; and identify
the gaps in the developmental immunotoxi-
cologyknowledge base.
Development ofthe
Immune System
Cellular and humoral immune responses in
the neonate differ both qualitatively and
quantitatively from those ofthe adult. These
differences are an anticipated result oflower
numbers and/or decreased functional capac-
ity ofleukocytes [e.g., T and B lymphocytes,
natural killer (NK) cells, and myeloid-lineage
cells] present in the early postnatal immune
system (1). The postnatal immune system
is, in turn, the product of a series of highly
regulated developmental events that include
sequential waves of hematopoietic cell
production, cellular migrations through
hematopoietic organs, cell-cell interactions
within these organs under microenvironmen-
tal influences, highly specific cytodifferentia-
tional steps, and final maturation, including
the acquisition ofdefinitive functional prop-
erties (2,3). Most available data regarding
ontogenesis ofthe vertebrate immune system
are derived from human and rodent studies,
and demonstrate multiple switching of
hematopoietic compartments during devel-
opment (4-8). Relatively limited data are
available in species other than humans and
rodents, but those that exist suggest similar
patterns ofimmune development. However,
the stage of development achieved at the
time of birth, and, thus, the degree of
immunocompetence in early postnatal life, is
variable from species to species (9).
Early in vertebrate development (e.g., at
approximately 24 hr in the chicken), meso-
dermal-derived hemangioblasts give rise to
the earliest progenitors of all blood cells.
These pluripotent stem cells are first detected
in the area vasculosa, a plexus of vessels
formed on the surface ofthe yolk sac before
the establishment ofclosed circulation (10).
Shortly thereafter, pluripotent stem cells
appear in blood islets within the yolk sac (5),
and, at approximately day 9 ofgestation in
the mouse, migrate via the bloodstream to the
fetal liver and spleen. The liverand, to a lesser
degree, the spleen then carry the burden of
hematopoiesis until shortly after birth (8).
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Fetal liver hematopoiesis is first detectable at
approximately day 10 ofgestation in mice
and at about the sixth week ofgestation in
humans (4,8). The mouse spleen actively
contributes to hematopoiesis from approxi-
mately day 15 ofgestation until several weeks
after birth, at which time erythropoietic ele-
ments predominate (6,8). Although the
spleen never completely loses hematopoietic
function in the mouse, this organ has largely
ceased hematopoiesis in humans by the time
ofbirth (but may regain hematopoietic func-
tion in abnormal situations) (11).
Perinatally in both mice and humans,
pluripotent stem cells in the liver migrate to
bone marrow as the liver becomes increas-
ingly devoted to metabolic function. The vas-
cular mesenchyme within the bone marrow
forms a supporting reticular network by ges-
tational days 17-18 in mice and by week 20
in humans upon which the migrating
pluripotent stem cells can seed and proliferate
(12). Waves ofgranulopoietic activity domi-
nate murine marrow hematopoietic function
from about day 19 ofgestation until approxi-
mately 3 months after birth. Limited erythro-
poietic activity begins in mouse bone marrow
after birth and in humans well before birth
(8). A limited number ofB cell progenitors
can be detected in mouse bone marrow on
day 19 ofgestation; they increase in number
until about 2-4 months ofage, atwhich time
they constitute approximately 20% of the
nucleated cell population. A limited number
ofT lymphocytes can be detected in murine
bone marrow at birth, and they slowly
increase to plateau at about 2-4 months of
age (6). In both mice and humans, the bone
marrow then serves as the primary site of
hematopoiesis throughout postnatal life.
The epithelial thymic rudiment forms at
gestational days 9-10 in the mouse (6,13),
after which colonization ofthe thymus by
precursor T cells from the fetal liver begins
on days 10-11 (13,14). These thymocytes
are initially double negative with respect to
CD4 and CD8 cell-surface antigens, then
develop sequentially to immature CD8+ sin-
gle positive and CD4+CD8+ (double posi-
tive) stages, and finally mature into CD4+ or
CD8+ thymocytes that migrate to the periph-
ery as functional T-helper and cytotoxic
T lymphocytes, respectively. Rearrangement
of T-cell receptor (TCR) gene segments
occurs during this maturation, resulting in
appearance ofdouble-positive thymocytes
expressing surface TCR (15,16). The TCR
complex that includes a product ofthe TCR
y-gene is present on fetal thymocytes by days
14-15 of gestation (17,18). At approxi-
mately day 17 offetal mouse development,
the TCR ac-heterodimer is expressed on the
majority of thymocytes (19). Anti-CD3
monoclonal antibody is able to activate
day-16 fetal thymocytes, however (20),
indicating that CD3-bearing day-16 fetal
thymocytes express a functional TCR before
TCR-ac4 structures are expressed (19).
In contrast to the mouse, where thymic
colonization occurs in the latter halfofgesta-
tion, thymic colonization and early T-cell
development occur in the first trimester of
fetal development in humans. Bloodborne
stem cells enter the developing thymus at
approximately 7 weeks ofgestation, with sub-
sequent differentiation occurring rapidly and
following a pattern similar to that seen in the
mouse. The majority of these thymocytes
express TCR ofthe y8 type at approximately
9.5 weeks ofgestation and ofthe ax3 type by
about 10 weeks ofgestation (1,21). Presently,
it is unclearwhether the diversityoftheT cell
repertoire in rodents and humans is lower at
birth than in adulthood. Further, the capacity
ofsuch T cells in rodents and humans at
birth to provide help for immunoglobulin
secretion is limited mainly to IgM produc-
tion. This may in part be due to reduced abil-
ity of T cells from neonates to produce
cytokines [e.g., interleukin (IL)-2, IL-4, and
interferon-y] required for activation of
T-helper (Th) cells, as well as macrophages,
NKcells, and cytotoxic Tlymphocytes (1).
B lymphopoiesis can be identified in
mouse fetal liver by days 12-13 ofgestation
(22). Pre-B cells can be found in the fetal liver
ofmice by day 14, and B lymphocytes, which
are for the most part restricted to IgM expres-
sion, can be found by days 16-17. The gen-
eral scheme ofearly B-cell development in
mice includes a) a series ofwell characterized
molecular steps involving the assemblyofgene
segments encoding the immunoglobulin mol-
ecule, b) heavy chain D-J rearrangements to
yield progenitor B cells, and c) light chain V-J
rearrangements to generate B cells expressing
complete cell-surface Ig (23-25). These mole-
cular events, which have been demonstrated
in both fetal liver and neonatal spleen in the
mouse, appear identical to those occurring
throughout life in adult bone marrow.
However, neonatal mouse B lymphopoiesis
differs from the adult mouse in the level of
expression ofcertain enzymes [e.g., terminal
deoxynucleotidyl transferase, precursor
lymphocyte-regulated myosin-like light chain,
and in major histocompatibility complex
(MHC) class II surface antigen expression].
Hayakawa et al. (22) suggested that such fetal
differences from adult B lymphopoiesis during
development may be related to differences in
susceptibility to tolerance.
IgM synthesis can be detected byapproxi-
mately weeks 10-12 ofgestation in human
fetal liver. Serum IgM concentrations areonly
approximately 10% ofadult levels at birth,
and do not reach adult levels until 1-2 years
ofage. Similarly, concentrations ofIgG in
serum do not reach adult levels for 4-6 years
after birth. Further, human neonates younger
than 2 years age are not able to mount
humoral responses to some antigens (e.g., car-
bohydrate antigens), an observation that may
in part explain the increased susceptibility of
infants to certain bacterial infections (e.g.,
Streptococcuspnenumoniae) (1).
Consequences of
Immunotoxicant Exposure
Prenaal Exposure
Organogenesis ofthe immune system occurs
during the prenatal and, to a lesser extent,
early postnatal periods ofmammalian devel-
opment. As might be predicted from this, the
perinatal period is a time ofhigh sensitivity to
immunotoxicants that cross the placenta or
enter the neonate via lactation. Postnatal
immunotoxic consequences from such chemi-
cal exposure during the initial establishment
of the immune organs may be both more
severe and more persistent than those that
occur in adult animals exposed at similar lev-
els [reviewed by Holladay and Luster (26)].
Indeed, for a growing list ofchemical agents,
the exposure ofpregnant animals to immuno-
toxicants at levels that produce limited tran-
sient effects in adults produces long-lasting
or even permanent immune deficits in
the offspring.
Chemical agents that cause developmental
immunotoxicity in rodents are diverse and
include halogenated aromatic hydrocarbons
(HAHs), polycyclic aromatic hydrocarbons
(PAHs), hormonal substances, therapeutic
agents, heavy metals and mycotoxins are sum-
marized as follows [modified from Holladay
and Luster (26)]:
* polycyclic halogenated hydrocarbons:
TCDD, PCBs, and PBBs
* polycyclic aromatic hydrocarbons: B[a]p;
methylcholanthrene; and 7,12-dimethyl-
benz[a]anthracene
* pesticides: hexachlorocyclohexane, chlor-
dane, diazinon, DDT, andcarbofuran
* fungicides: hexachlorobenzene
* heavy metals: methyl mercury, lead, and
cadmium
* hormonal substances: estrogens/
diethylstilbestrol (DES), testosterone, and
cortisone
* therapeutic agents: acyclovir, busulfan,
cyclophosphamide, and cyclosporin A
* mycotoxins: T-2 toxin
* irradiation: Xrays.
With the exception ofa limited database
in humans who were exposed to therapeutic
immunosuppressive drugs or to the nons-
teroidal estrogen DES during gestation,
details regarding postnatal consequences from
early human exposure to known adult
immunotoxicants remain largely unavailable.
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A relatively new and growing concern is that
such early human exposure to immunotoxic
compounds may not only cause postnatal
immunosuppression, but may also result in
increased expression of aberrant immune
responses (e.g., hypersensitivity and auto-
immune disease).
HAHs. Considerable effort has been
devoted to understanding the effects ofPAHs
on the developing immune system. The most
studied compound in this group ofchemicals
for immunotoxicity is TCDD. Much ofthe
immunotoxicity ofTCDD and congeners of
TCDD (halogenated biphenyls, chlorinated
dibenzofurans, and other chlorinated diben-
zodioxins) is directly proportional to the
binding affinity ofthe individual congeners
to the aryl hydrocarbon (Ah) receptor (27).
For this reason, many ofthese agents produce
a similar pattern ofimmunotoxic responses in
animals (28). TCDD in particular produces
profound thymic atrophy in all species exam-
ined [reviewed by Vos and Luster (29)].
Further, when administered during the matu-
rational development ofthe immune system,
TCDD causes more persistent immunosup-
pression than if given in adult life (30).
Thymic atrophy in neonates and adults
occurs after remarkably low-level exposure to
TCDD and has been well characterized.
TCDD crosses the mouse placenta relatively
poorly [i.e., < 0.5% of an oral dose (31)];
however, single-dose or subacute exposure of
pregnant mice to TCDD in the low mil-
ligram-per-kilogram range causes a highly sig-
nificant involution ofthe fetal thymus as well
as inhibition ofthymocyte differentiation
(32). Such exposure to TCDD results in
inhibited T-cell responses lasting 8-10 weeks
after birth in exposed mice (33). Other effects
on cell-mediated immune function after pre-
or perinatal TCDD exposure include sup-
pression ofT-cell mitogen responses (34),
skin graft rejection times, graft-versus-host
reactivity (35), and delayed hypersensitivity
(30,36-39). In addition, perinatal TCDD
exposure increases susceptibility to challenge
with infectious agents or syngeneic tumor
cells (30). Thus, the collective available data
indicate that TCDD exposure during devel-
opment ofthe immune system results in a rel-
atively long-lasting postnatal impairment of
cell-mediated immune function.
Polyhalogenated biphenyls [polychlori-
nated biphenyls (PCBs) and polybrominated
biphenyls (PBBs)] represent a heterogeneous
class ofHAHs that have been associated with
immunological effects in humans and animals
(40-42). Reports ofdevelopmental immuno-
toxicity caused by PCB or PBB exposure vary
from little or no observed toxicity to highly
significant immune system alterations. For
instance, when PBBs were administered
during gestation in mice and rats, a variety of
immune parameters including hematology,
serum immunoglobulin and antibody titer,
delayed hypersensitivity response, lympho-
proliferative responses, and several macro-
phage functions were not affected in the
offspring (42). These authors also found that
calves inadvertently exposed to PBB in utero
displayed no significant alterations in
immune responses. When pregnant mice
were dosed with 0.5 mg/kg/day ofthe PCB
3,4,5,3 ',4',5'-hexachlorobiphenyl (HCB)
beginning at the day of implantation, very
marginal effects on the developing immune
system were again observed (43). Similarly,
feeding pregnant mice throughout gestation
and lactation with various combinations of
lead and/or PCB resulted in negligible effects
on the ability ofthe offspring to mount an
immune response (44). However, when lead
alone was administered throughout gestation
and lactation, 35- to 45-day-old rats dis-
played reduced thymic weights and delayed
hypersensitivity responses and inhibited lym-
phocyte proliferation (45). These reports
indicate that certain PBBs and PCBs are not
potent developmental immunotoxicants.
In contrast to the above results, significant
alterations were reported in peripheral lym-
phocytes of4-week-old piglets after perinatal
exposure to a commercial mixture of PBB
(Firemaster BP-6) (46). Four-week-old mice
exposed prenatally to a commercial PCB mix-
ture (Kanechlor 500) displayed T-helper
activity reduced to 20% ofcontrol levels (47).
In another report, in utero exposure ofmice
to PCB resulted in fetal thymic hypoplasia
and inhibited lymphoid cell development in
thymic organ culture (thymi taken from
14-day embryos) (48). Thus, published
reports have varied considerably regarding the
toxicity of halogenated biphenyls to the
developing immune system. These different
immunotoxicity outcomes may in part be the
result ofdifferences in structure ofthe con-
geners evaluated. In particular, for some toxic
end points, PCBs with chlorines in the para
positions and in at least one ofthe metaposi-
tions ofeach ring, but not in any ortho posi-
tion, are the most toxic members of this
chemical class (49). These PCBs, including
3,3',4,4'-tetrachlorobiphenyl (TCB),
3,3',4,4',5-pentachlorobiphenyl (PeCB), and
3,4,5,3',4',5'-HCB, bind the Ah receptor
with relatively high affinity (though with less
avidity than TCDD) (50). Mono- and ortho-
chlorinated biphenyls, in contrast, are weak
Ah receptor ligands and thus do not produce
Ah-receptor mediated immunotoxicity at lev-
els comparable to congeners with higher
receptor affinity. In support ofAh receptor
binding affinity as a mechanism explaining
divergent reports of PCB immunotoxicity,
median effective dose (ED50) values for
inhibition of the developing bursa of
Fabricius in chick embryos were 4 pg PeCB,
50 pg TCB, and 300 pg/kg egg HCB,
whereas the mono-ortho-chlorinated analogs
of TCB and PeCB were 1,000 times less
potent inhibitors ofbursal development than
PeCB. When mouse thymi were taken from
gestational day 15 mouse fetuses and treated
ex vivowith TCDD or PCB in organ culture,
inhibited thymocyte development again cor-
related with Ah receptor binding affinity. For
example, PeCB was only one-tenth as potent
(EC50 = 2 x 10-9 M) as TCDD (EC50 = 2 x
10-10 M) in inhibiting thymocyte develop-
ment, whereas the potencies of HCB and
TCB were approximately one-hundredth that
ofPeCB. No inhibition ofthymocyte devel-
opment was produced in this system by con-
centrations ofmono-ortho-chlorinated PCB
as high as 106 M (50).
There are reports that document develop-
mental immunotoxicity of certain mono-
cyclic and polycyclic halogenated pesticides
and pesticide contaminants, including the
fungicide hexachlorobenzene (51); the herbi-
cide contaminant 3,3',4,4'-tetrachloro-
azoxybenzene (52); and the insecticides
hexachlorocyclohexane (53), diazinon, and
carbofuran (54) and chlordane (55).
Hexachlorobenzene exposure at 0.5
mglkg/day throughout gestation resulted in
long-lasting (into adulthood) depressed
delayed-type hypersensitivity (DTH)
responses and decreased numbers ofsplenic
B cells in exposed mice in utero (51). When
pregnant mice were exposed to higher levels
of hexachlorobenzene, Barnett et al. (51)
noted a significantly impaired mixed lym-
phocyte response. In contrast, rats exposed
pre- and postnatally via their diet to approxi-
mately 4, 20, or 100 mg/kg hexachloroben-
zene had significantly enhanced humoral
immune function and DTH responses (56).
The reasons for this different observation in
rodents exposed to hexachlorobenzene is
unknown but may be due to dose level. In
this regard, when pregnant mice were
exposed to 10 or 100 mg/kg body weight
hexachlorocyclohexane (HCH), the DTH
response at postnatal day 10 was significantly
increased in mice exposed to 10 mg/kg
HCH and significantly impaired in mice
exposed to 100 mg/kg HCH (53). Spleen
cell responses to concanavalin A (ConA) and
lipopolysaccharide (LPS) were 2- and 8-fold
higher, respectively, and the number ofanti-
body plaque-forming cells (PFC) was 2-fold
higher relative to control values in pups from
the 10 mg/kg group, whereas neither mito-
gen nor the PFC responses were altered by
100 mg/kg HCH. Immunostimulation has
been described at certain (usually low) dose
levels of chemicals that are otherwise
immunosuppressive, although the biological
significance is unknown (57-59P).
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Selective and highly persistent immune
alterations have also been observed in mice
after gestational exposure to the organochlo-
rine insecticide chlordane. Mice exposed to
chlordane during fetal life display significant
depression ofcell-mediated immunity that is
still present 101 days after birth, reduced
numbers ofgranulocyte-macrophage colony-
forming units and colony-forming units in
the spleen at 200 days ofage, and long-term
depression ofboth DTH and mixed lympho-
cyte reactivity (55,60). It is noteworthy that
these immune effects are either reduced or
not observed in adult mice exposed to chlor-
dane at dose levels equal to those given to the
pregnant mice.
PAHs. Immunosuppressive PAHs [e.g.,
B[a]P, methylcholanthrene, and dimethyl-
benz[a]anthracene] have become ubiquitous
environmental contaminants as a result of
their occurrence in petroleum, coal and coal
tars, soot, air pollutants, tobacco smoke, and
cutting oils (61-63). The ability ofcertain
PAHs to cross the placenta (64) as well as to
produce immunosuppression in adult animals
raised questions about the intensity and per-
sistence ofeffects ofthese agents on the devel-
oping immune system. Urso and Gengozian
(65,66) and Urso and Johnson (67) reported
severely depressed humoral immune function
in mice exposed to B[a]P from days 13-17 of
gestation. In the latter ofthese reports (67),
these authors also observed highly persistent
(still present at 18 months ofage) impair-
ment ofcell-mediated immunity in offspring
in the form ofsuppressed mixed-lymphocyte
and graft-versus-host responses. Increased
tumor frequency was further observed in the
mice exposed to B[a]P before birth, suggest-
ing the lesion to the developing immune sys-
tem may provide a favorable environment for
the growth ofneoplasms.
The toxicity ofB[a]P is in part due to
production of a highly reactive epoxide
metabolite by microsomal mixed-function
oxidase enzymes that covalently bind DNA
and other nucleophilic intracellular macro-
molecules. Thus, rapidly proliferating cells,
such as those composing the immune system,
are targeted (68). Interestingly, a study evalu-
ating the covalent binding ofB[a]P in fetal
mouse tissues found that liver hematopoietic
cells were the most active (69). Further, the
extent oftransplacental enzyme induction
compared to control was greatest in hemato-
poietic cells (18-fold), followed closely by
whole fetal liver (16-fold) (67,69). Such
results indicate that fetal liver, the primary
hematopoietic organ in the fetus (4,6-8), and
its hematopoietic cells are specific targets of
B[a]P, and may explain, at least in part, the
significant toxicity to the developing immune
system resulting from exposure to this com-
pound. In addition to covalent interaction
with DNA, PAHs also bind the Ah receptor
and thus may cause TCDD-like immune
effects through noncovalent interactions of
the receptor-ligand complex with DNA. The
observation ofa TCDD-like inhibition of
thymocyte differentiation in day-18 fetal
mice exposed to TCDD from days 13-17 of
gestation may suggest Ah-mediated immuno-
toxicity from PAHs (70). In addition to
inhibited thymocyte maturation, these
authors reported severe fetal thymic atrophy
and thymocyte depletion and decreased fetal
liver hematopoietic cell counts. Prolymphoid
cells (both T and B precursors), identified by
cell surface antigen expression and by the
presence ofterminal deoxynucleotidyl trans-
ferase, were also significantly decreased. These
authors hypothesized that decreased numbers
offetal liver prothymocytes may contribute to
fetal thymic atrophy via reduced colonization
ofthe thymus, and that reduced pre-B cells
may relate to the depressed humoral immu-
nity caused by prenatal exposure to B[a]P.
Similar effects on the development ofimmu-
nity in mice exposed to 7,12-dimethylben-
zanthracene have been reported (71).
Steroidhormones (estrogen). An altered
prenatal hormonal environment has been
associated with changes in postnatal immune
function in mice (72). However, the role of
sex steroids in the development of the
immune system remains poorly understood
at best. Reports in the literature indicate that
exogenous androgenic (73) or estrogenic
compounds (74-81) can alter normal devel-
opment ofthe immune system. The available
data largely report effects ofestrogen and
estrogenic compounds (e.g., zearalenone and
the nonsteroidal estrogen DES). Exposure to
pharmacologic or suprapharmacologic levels
ofeither steroidal or nonsteroidal estrogens
results in numerous alterations of immune
function, particularly when administered
perinatally. The effects ofsuch administra-
tion in rodents include myelotoxicity
(82,83), suppression ofcell-mediated immu-
nity (84), pronounced thymic atrophy
(85,86), depression of NK cell activity
(87,88), and stimulation ofthe reticuloen-
dothelial system (81,89). Studies examining
postnatal immune function in humans
exposed in utero to exogenous estrogen are
limited to a few retrospective evaluations of
adults exposed during pregnancy to DES.
These currently unconfirmed reports suggest
possible adverse immune effects in humans,
including altered T-lymphocyte and NK cell
function in adulthood (76,90) and increased
incidence ofautoimmune diseases (74,91).
The available rodent data support the
indication in humans that developmental
exposure to DES may alter postnatal
immunocompetence. Long-term impairment
of both humoral (antibody production),
innate (i.e., NK cell activity), and cell-
mediated (T lymphocyte mitogen respon-
siveness, graft-versus-host reaction, and
delayed hypersensitivity) immune function
has been associated with perinatal DES expo-
sure in mice (75-78). Depression of these
functional assays has further been associated
with increased postnatal susceptibility to
viral-induced mammary tumors and to trans-
planted primary and carcinogen-induced
tumors (79,80). It has been suggested that a
possible relationship may exist between pre-
natal DES exposure and neoplastic growth in
humans, including clear-cell adenocarcinoma
ofthe vagina (92,93).
Lead Administration oflead throughout
gestation and lactation in rats resulted in
reduced thymic weights and inhibited DTH
and lymphoproliferative responses at 35-45
days ofage (45). Lead exposure in both rats
and chickens during early development also
caused persistent shifts in humoral immune
function, apparently as a result ofeffects on
T-helper cells (94). It is important to note
that the dose levels of lead used in these
studies did not cause immunologic effects in
adult rats. Bunn et al. (95) reported altered
Thl-/Th2-associated functions in female but
not male rats after exposure to lead during
development. Further, the lack ofmaternal
influence in the developing chicken model
used by these authors suggests a direct
immunomodulatory effect oflead on the
developing immune system, at least in this
species. Chen et al. (96) also suggested that
there are periods ofgreater sensitivity to
impairment by lead exposure during rodent
development.
Therapeutic agents. Many chemothera-
peutic agents (e.g., alkylating antineoplastic
drugs such as cyclophosphamide or chloram-
bucil) are potent immunosuppressants simply
because they are powerful antiproliferative
agents, and many aspects ofa functioning
immune system require active proliferation.
Other drugs such as therapeutic immunosup-
pressants are specifically administered for
their immunotoxicity, to control autoim-
mune and hypersensitivity diseases, to control
certain inflammatory conditions, or to pre-
vent organ transplant rejection. Human preg-
nancy can exacerbate autoimmune disease,
requiring therapeutic intervention during this
critical time. Further, recent advances in
organ transplant success have resulted in
increasing numbers ofwomen becoming
pregnant after an organ or tissue (allograft)
transplant procedure. These women require
therapeutic immunosuppressants throughout
pregnancy to prevent allograft rejection. Thus
the probability ofimmunotoxic drug expo-
sure during pregnancy may in some cases be
increasing. In other instances, women who
are unaware they are pregnant may be
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exposed to a wide variety of potentially
immunotoxic therapeutic regimens.
The antileukemic alkylating agent busulfan
caused severe thymic hypoplasia in mice
treated with a single dose during midgesta-
tion (97), raising questions about the similar
effects ofother therapeutic alkylating agents.
Cyclophosphamide has been widely used as
an antineoplastic agent and, previously, as an
immunosuppressant both after organ trans-
plant and for autoimmune disease control
(98,99). Further, cyclophosphamide treat-
ment in adults is particularly toxic to B lym-
phocytes (100,101) and results in impaired
antibody production to T-dependent and
T-independent antigens (102,103), decreased
lymphoproliferative responses (103), impaired
NK cell activity (104), and impaired host
resistance to infectious agents and syngeneic
tumor cells (105). Chickens exposed to
cyclophosphamide during embryonic/neona-
tal development displayed near-total eradica-
tion of the lymphocyte population within
the bursa ofFabricius, and complete suppres-
sion of humoral immunity (106,107).
However, studies in pregnant mice found no
differences in spleen or thymus weight or
histology, hematological profiles, antibody
responses, or DTH responses, even at doses
of cyclophosphamide that significantly
decreased fetal body weight (108). Cyclo-
phosphamide is metabolized to an active
alkylating agent, and both the parent com-
pound and the active metabolite cross the
placenta (109). Fetal metabolism ofcyclo-
phosphamide does not appear to occur, how-
ever; thus, teratogenic or fetotoxic doses of
this drug may be required before immuno-
toxic levels ofmetabolite are formed in the
fetus (108).
In the past, glucocorticoid hormones and
cytotoxic (chemotherapeutic) drugs were
widely used to inhibit tissue allograft rejec-
tion; however, prolonged use and/or use of
larger doses ofthese drugs was severely lim-
ited by numerous, and in many cases serious,
side effects (110). Thus, considerable
research effort has been directed toward the
development of new and more effective
immunosuppressive drugs. The potent
immunosuppressant, cyclosporin A (CsA),
was introduced into clinical trials in 1978
(111) as a result ofsuch efforts, and since has
become the most widely used agent for the
prevention ofhuman organ transplant rejec-
tion (112-114). CsA is now considered the
major reason for the present success oforgan
transplant surgery (115). Effective therapeu-
tic immunosuppression with CsA, however,
often requires simultaneous administration
ofadditional immunosuppressive drugs [e.g.,
azathioprine (AZA), 15-deoxyspergualin,
mizoribine, didemnin B, and corticosteroids,
including prednisolone (116-123)]. More
powerful and less toxic antirejection drugs
are still highly desired and are currently
being developed and tested.
Numerous successful births have been
reported in women receiving potent
immunosuppressants throughout pregnancy,
including CsA (117,118,124-126), AZA
(117,118,127,128), and prednisolone
(118,129,130). Limited amounts ofCsA or
AZA cross the placenta; however, observa-
tions oftransient neonatal thrombocytopenia,
leukopenia, and hypoplasia ofthe lymphatic
system in children exposed to CsA (124) or
to AZA and prednisolone (131,132) during
pregnancy suggest that some developmental
immunotoxicity results from maternal expo-
sure to these agents. The long-term immune
consequences (e.g., postpuberty) from such
exposure in these children remains unknown.
Compared toAZA, CsAtreatment during
human pregnancy carries a higher risk ofpre-
mature delivery as well as for the delivery of
small-for-gestational-age (SGA) babies. In a
recent studyof238 women receivingavariety
ofimmunosuppressive drug regimens during
pregnancy, the rates for both prematurity and
SGA infants were high (49 and 29%, respec-
tively) (133). Regimens that included CsA
resulted in 66% prematurity (43% with
AZA) and 56% SGA babies (19% with
AZA). However, data from this study indi-
cated, in contrast to previous reports, that
AZA may carry a higher risk ofcongenital
malformation than CsA. Birth defects
presently associated with CsA administration
during pregnancy include cataracts (116,134),
dysmorphic facial appearance (135), cleft
palate (136), aseptical necrosis ofthe femoral
head, and additional fetal malformations
induced by recurrent viral infection (137).
The resultant uncertainty surrounding the
potential ofthese agents to induce develop-
mental malformations in humans, as well as
regarding "safe" levels of these agents to be
administered during pregnancy, was under-
scored by the results of a recent survey of
pediatric gastroenterologists in which the
"vast majority ofresponders were not certain
what to recommendwith respect to the use of
immunosuppressive agents prior to and dur-
ing pregnancy" (117). This remains true
largely because the primary clinical objective
of such immunosuppressive therapy, until
quite recently, has been maintaining the life
ofthe recipient rather than allowing recipient
individuals to conceive and bear children. It
may be important that these studies did not
include neonatal immune end points as a
focus, especially with the consideration that
the immune system is the target organ ofthe
drugs beingadministered.
Rodent studies that use fetal thymic
organ culture techniques demonstrated that
CsA exposure alters early development of
thymocytes within the fetal thymus,
completely blocking the generation of
mature T cells (112), indicating that the fetal
immune system may be targeted by maternal
dosing with CsA. Because low levels ofCsA
cross both the rat (138) and human
(133,139,140) placenta, it is reasonable to
anticipate that CsA may affect the same tar-
get organs in the embryo as in the adult.
Further, laboratory mice exposed perinatally
to CsA displayed hypoplastic peripheral lym-
phatic organs, impaired intrathymic thymo-
cyte differentiation, absence ofmature T cells
in lymph nodes andspleens, and lackoffunc-
tional T-cell reactivity (141). However, in
these studies mice were exposed to CsA only
during the third trimester ofpregnancy, with
continued exposure for as long as 28 days
postnatally. Thus, the consequences ofearlier
prenatal exposure, as well as the contribution
ofprenatal exposure alone, to immune alter-
ationswere not determined.
CsA also interferes with tolerization of
developing T lymphocytes after syngeneic
bone-marrow reconstitution, resulting in
autoimmunity (i.e., syngeneic graft-vs.-host
disease) in the host animals (142,143). Such
results raise questions about the ability of
CsA to induce or exacerbate autoimmune dis-
ease in gestationally exposed individuals.
Zacharchuk et al. (144) recently found that
the susceptibility of thymocytes to clonal
deletion changes during ontogeny. Studies by
these authors indicate that there is a relatively
synchronous wave of maturing thymocytes
that are susceptible to deletion signals during
fetal life and shortly after birth, but not 7
days after birth. Such an observation is in
agreement with the current understanding of
neonatal tolerance and further suggests that
failure to induce tolerization in glucocorti-
coid-exposed 1-week-old mice reflects an
alteration in susceptibility to normal clonal
deletion during that time (144). Indeed, a
recent study ofnewborn mice dosed daily
with CsA during the first week ofpostnatal
life demonstrated the subsequent develop-
ment oforgan-specific autoimmune disease
(145). For such reasons, ablactation has been
recommended in women treated with CsA
during pregnancy because ofthe transfer of
CsA equivalent to 5% ofan immunosuppres-
sive dose into the breast milk, and because of
the potential toxicity and unknown side
effects of CsA on the child's immunologic
system (146). Ofperhaps greater importance,
it has now been determined that the blood of
such newborns contains CsA concentrations
as high as 65-85% ofmaternal levels (147).
Taken together, these studies raise questions
regarding the ability oftransplacental CsA
exposure to contribute to the expression of
autoimmune disease later in the life of
gestationallyexposed individuals.
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The use oftherapeutic immunosuppres-
sants during pregnancy thus represents a rela-
tively new area ofhuman developmental
exposure to immunotoxic agents. In some
regards, the effect ofthese drugs on the devel-
oping immune system have largely been dis-
regarded in the assessment of risk to the
unborn despite the known heightened sensi-
tivity of the immune system to chemical
insult during development.
Prenatal chemical exposure andpost-
natalautoimmune disease. The observation
that CsA treatment in irradiated rodents leads
to expression of autoimmune disease after
bone marrow transplantation raises questions
about other chemical agents that might have
this effect. TCDD produces fetal thymic
effects in vivo similar to the effects ofCsA in
fetal thymic organ culture, including inhib-
ited thymocyte maturation and reduced
expression ofthymic MHC class II mole-
cules. These observations led to the sugges-
tion that gestational exposure to TCDD may
interfere with normal development ofselftol-
erance [reviewed by Holladay (148)]. It has
also been suggested that humans exposed to
DES during immune development may dis-
play increased incidence ofautoimmune dis-
ease. A retrospective study ofwomen (1,711
individuals) exposed to DES during preg-
nancy found that the overall frequency ofany
autoimmune disease was 28.6/1,000 com-
pared to 16.3/1,000 among unexposed con-
trols (significantly different atp = 0.02) (74).
The autoimmune diseases evaluated included
systemic lupus erythematosus, scleroderma,
Grave disease, Hashimoto thyroiditis, perni-
cious anemia, myasthenia gravis, thrombocy-
topenic purpura, rheumatoid arthritis,
regional enteritis, chronic ulcerative colitis,
multiple sclerosis, chronic lymphocytic
thyroiditis, Reiter syndrome, and optic neuri-
tis. When these autoimmune diseases were
considered individually, however, only
Hashimoto thyroiditis occurred significantly
more often in the exposed women (p = 0.04).
A similar evaluation of 1,173 humans
exposed to DES during development (1,079
females and 94 males) found increased
asthma, arthritis, and diabetes mellitus
compared to prevalence rates for these dis-
eases in the general population (91).
However, in a more recent study evaluating
rates ofallergy, infection, and autoimmune
disease in DES-exposed individuals (253 men
and 296 women) matched with similar unex-
posed individuals (241 men and 246
women), no differences in disease occurrence
were detected (149). Baird et al. (149) con-
cluded that a larger sample was needed to
evaluate DES-associated risk ofautoimmu-
nity because autoimmune diseases are rela-
tively rare in the human population. Thus,
preliminary studies ofhumans exposed before
birth to DES suggest the possibility ofpost-
natal immune alterations, including increased
autoimmune disease.
Rodent studies that evaluated increased
expression ofautoimmune disease after devel-
opmental immunotoxicant exposure have
been limited. However, a recent report indi-
cates that mice predisposed to the develop-
ment of autoimmune disease display
exacerbated disease if exposed to DES or
TCDD during gestation. Silverstone et al.
(150) found that a single fetal exposure to
TCDD in NZB x SWR (SNF1) mice signifi-
cantly reduced the time to postnatal onset of
autoimmune lupuslike nephritis in the male
offspring. These authors reported a similar
observation for DES, i.e., a single fetal expo-
sure of SNF1 mice to DES induced auto-
immune nephritis in male offspring between
5 and 10 months ofage. Female SNF1 mice
develop this autoimmune syndrome sponta-
neously during the first year oflife; however,
male mice do not display significant autoim-
munity before 1 year ofage. This report sug-
gests that prenatal exposure to certain
immunotoxicants mayplay a role in postnatal
expression ofautoimmunity.
Postatal ImmunotoxicantExposure
There are fewdevelopmental studies in which
experimental animals have been exposed to
immunotoxicants only during the postnatal
period.
Although it is not an immunotoxic agent,
malnutrition during earlychildhood adversely
affects the immune system. Dietary protein
deprivation in malnourished young children
between 1 and 3 years ofage resulted in a
number of immune deficiencies. These
included decreased IgG and trends toward
lower IgA and IgM levels, decreased cuta-
neous hypersensitivity responses, decreased
T lymphocyte responses to phytohemag-
glutinin (PHA), and reduced responses to
Salmonella typhivaccine (151). Four- to six-
week-old mice fed a lowprotein dietdisplayed
decreased T cells and decreased responses to
PHA and allogeneic cells in the mixed-
lymphocyte response (MLR), as well as retar-
dation of immune maturation (152). Zinc
deficiency in the diet oflactating mouse dams
resulted in pups that displayed retardation of
thymus and spleen development, depressed
T-cell mitogen responses, and the absence of
detectable IgM and IgG (153-155).
The administration of certain drugs
during early postnatal life can also result in
altered immune function later in life. For
example, 1-day-old mice and rats exposed to
cortisol acetate or hydrocortisone, respec-
tively, displayed thymic atrophy and reduced
antibody responses to sheep red blood cells
(SRBC) (156,157). When given to 1- to 5-
day-old mice, DES, a nonsteroidal drug
having estrogenic activity, resulted in a
number of immune abnormalities. These
abnormalities included reduced T- and B-cell
mitogen responses to PHA and LPS, respec-
tively; reduced antibody responses to SRBC
and LPS; reduced T-helper cells; and reduced
NKcell activity (88,158,159).
Toxic chemicals administered to young
animals may also alter immune function,
which maybe more severe than that in adults
or which may persist for a longer period of
time. For example, the exposure ofrat pups
to di-n-octyltin dichloride during the first 3
weeks oflife resulted in suppression ofthe
PHA response, which persisted up to 10
weeks of age (160). Rat pups exposed to
cocaine from postnatal day 1-21 had
decreased peripheral blood lymphocytes on
day 22, whereas pups exposed to both
cocaine and ethanol had decreased total IgM
levels (161). Weanling (i.e., 25-day-old) rats
dosed 4 times over 17 days with 3,3',4,4'-
tetrachloroazoxybenzene had reduced thy-
mus weights, antibody responses to SRBC,
peritoneal macrophage chemiluminescence,
and bone marrow cellularity. These effects
were greater in rats exposed as weanlings
compared to adults (i.e., 56 days old at the
start ofdosing) (52).
Comparison ofSimilarities and
Differences Between Humans
and LaboratoryAnimals
Direct comparison ofimmune development
between human and animals is complicated
by several factors. However, the most signifi-
cant difference lies in the developmental
maturity ofthe immune system before and
after parturition. This difference has been
linked to the length ofgestation. For exam-
ple, animalswith short gestation periods (e.g.,
mice, rats, rabbits, and hamsters) have rela-
tively immature immune systems at birth
compared to humans, with significant
immune development occurring postpartum.
Nevertheless, there are more similarities than
differences in the ontogeny of the human
compared to laboratory animal immune sys-
tems. In fact, a significant amount of our
knowledge about human immune system
development has been achieved because of
animal research.
To present the similarities and differences
in the ontogeny ofimmune system cells for
which there are data in both humans and
mice, we used a convention to compare pre-
natal immune system maturational landmarks
between the species. The period ofgestation
for the mouse is approximately 20 days; that
for the human is 40 weeks. Therefore, each
day ofgestation for a mouse is approximately
equivalent to 2 weeks of gestation for the
human. We expressed the time ofgestational
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development for each maturational landmark
for which there are comparable data for the
human and the mouse, as a decimal portion
(dp) of the respective gestational periods
(Table 1). For example, ifa specific matura-
tional landmark occurs on week 10 for the
human and on day 12 for the mouse, the dp
would be 10/40 = 0.25 for the human and
12/20 = 0.60 forthe mouse.
Embryonic hematopoietic stem cells in
the fetal yolk sac begin to migrate in the
human fetus at approximately 5 weeks (dp =
0.125), which results in the presence oflym-
phocyte precursors in the liver by 7 weeks
(dp = 0.175) and in the thymus after 9 weeks
(dp = 0.225) (162). At 10 weeks (dp = 0.25)
the fetal thymocytes express the T-cell
markers CD3, CD4, CD5, and CD8 (163).
Lymphocytes begin to appear in peripheral
blood shortly after their appearance in the
thymus and then in the spleen (164). In the
mouse, the thymic epithelial anlage is colo-
nized by bone marrow-derived stem cells on
approximately gestation day 11 (dp = 0.55).
By day 14 (dp = 0.70), murine thymocytes
express CD4 and CD8 (165). For these mat-
urational landmarks the mouse is chronologi-
cally 2- to almost 3-fold more immature than
the human, respectively.
PHA-responsive lymphocytes in the
human fetal thymus are detectable by 12
weeks (dp = 0.3), with splenic and peripheral
blood lymphocyte responsiveness to PHA
detectable approximately 4 weeks later (dp =
0.4) (166). Responses to Con A have been
observed with thymus cells at 13-14 weeks of
gestation (dp = 0.35) and with spleen cells at
approximately 18 weeks ofgestation (dp =
0.45) (167). At 11-15 weeks ofgestation (dp
= 0.275-0.375), lymphocytes from human
fetuses are capable of stimulating and
responding to allogeneic lymphocytes in an
MLR (168). On the other hand, mouse thy-
mocytes only begin to respond to PHA, Con
A, and in an MLR by gestation day 17 (dp =
0.85), which is greater than a 2-fold delay
compared to the human. Although the levels
ofthymocyte responsiveness to PHA and in
the MLR in mice are similar to adult levels,
Con A responsiveness does not reach adult
levels until 2-3 weeks afterbirth (169).
Table 1.Time ofgestational development (dp).
Maturational landmarks Human Mouse
sig expression on B cells 0.10-0.15 0.85
Fetal liver hematopoiesis 0.15 0.50
firstdetected
Lymphocyte precursors 0.23 0.55
in thymus
Mitogen responsive 0.35 0.85
hymocytes
Functional NK cells 0.35 > 1.0
Pluripotent stem cells seed 0.50 0.85
The development offunctional NK cells
in the human fetus occurs at 28 weeks of ges-
tation (dp = 0.35), with full-term newborns
displaying peripheral blood NK activity at
approximately 60% that ofadult levels (170).
In contrast, NK cell activity in mice is absent
at birth and does not begin to appear until
about 3 weeks ofage (171).
The development of B lymphocytes in
humans begins at approximately the same
time as T lymphocytes. B lymphocytes (i.e.,
lymphocytes bearing sIgM and sIgG) are first
found in the liver at about 8 weeks of gesta-
tion (dp = 0.10) and in the spleen at about 12
weeks (dp = 0.15). IgD- and IgA-bearing cells
are found at 12 weeks of gestation (dp =
0.15). Adult levels ofB lymphocytes bearing
slg ofall classes are reached by 14-15 weeks
of gestation (dp = 0.35) (172). However,
human neonatal B lymphocytes are function-
ally defective in their capacity to generate
antibody-producing cells in vitrocompared to
B cells from adults. In general, B lymphocytes
ofhumans are inherently immature at birth.
Although a small number ofIgM-producing
cells are detected, no IgG- or IgA-producing
cells can be identified. The ability ofB cells to
produce antibodies ofthe IgG and IgA dasses
increaseswith age, with adult levels reached by
5 and 12 years of age, respectively (173). In
fetal mice, B cells expressing sIg appear in the
liver, spleen, and bone marrow on day 17 (dp
= 0.85) (6), which represents an approximate
3-fold delay compared to the human. In mice,
antibody responses to T-cell-independent
antigens occur soon after birth and reach
near-adult levels by 2 or 3 weeks. In contrast,
T-cell-dependent antibody responses in mice
begin after 2 weeks and do not reach adult
levels until 6-8 weeks ofage (174).
It is not clear why there are such delays
in B lymphocyte function. Deficiencies in IgG
and IgA responses during the early period of
life have been described as reflecting regula-
tion byT cells (suppressor cells) as opposed to
a deficiency in B cells. This high-suppressor
T-cell activity has been reported to exist
throughout infancy with decreasing intensity
and disappears by approximately 2 years of
age or later (173). On the other hand, a case
has been made that deficient B-cell function
during the first several years oflife is due to a
B-cell defect or immaturity rather than to a
negative influence by T-suppressor cells or
monocytes (172,175). In any event, it has
been postulated that the greater susceptibil-
ity of human newborns to certain bacterial
infections is due to deficient B-cell function,
particularly because of the delay in produc-
tion of IgG and IgA antibodies (172).
Infants appear to respond well to T-cell-
dependent antigens primarily through ade-
quate production of IgM. However, they
respond poorly or not at all to antigens such
as the polysaccharide antigens found on the
cell walls of several infectious bacteria,
which also contributes to increased suscepti-
bility to infections (175). It is interesting to
note the dichotomy between humans and
mice in the maturation ofantibody responses
to T-cell-dependent and -independent
antigens.
The immune responsiveness of human
neonates appears to be influenced by their
sensitization to antigens in utero and during
early postnatal life. There is ample evidence
from laboratory studies to demonstrate that
when animals are raised from birth in a germ-
free environment there is a delay in lymphoid
development (176). Germ-free animals have
significantly reduced levels ofIg, which is due
to a 2-5 times lower rate of Ig synthesis.
Synthesis of IgA and IgM is more affected
than IgG synthesis in a germ-free environ-
ment. The number ofplasma cells in these
animals is approximately 10 times lower than
in normal animals (172). Further, germ-free
animals have a difficult time replacing mater-
nal IgG, which is transported during gesta-
tion across the placenta, with a sufficient
production ofIgG oftheir own.
At birth nearly all ofthe IgG in the new-
born human is ofmaternal origin. During the
first 3-6 weeks oflife, there is an exponential
decrease in IgG that reaches its lowest level
between 1.5 and 3 months of age, when IgG
synthesis by the newborn begins; however,
adult IgG levels are not reached until 5-6
years of age. On the other hand, IgM levels
rise rapidly during the early months oflife,
with IgM at 75% of adult levels within 12
months oflife. Only 20% ofadult IgA levels
are present at 1 year; adult levels are reached
only after 10 years of age (177). The early
increase in IgM levels in newborns parallels
the development of natural antibodies to
enterobacteria. Studies with humans indicate
that exposure to various nonpathogenic
microorganisms or vaccines early in life gives
rise to higher serum Ig titers than seen in
noninfected/nonimmunized infants (177).
Human fetal macrophages originate
from hemopoietic stem cells and appear in
tissues through the circulation after vascular-
ization. In mice, immature macrophages can
be found in the yolk sac at approximately
gestation day 10-11 and then in other tis-
sues and in circulation at day 12 or later
(178). Although fetal macrophages generally
lack the ability to kill certain bacteria after
phagocytosis, neonatal rodents possess bacte-
ricidal activity, albeit less than that ofadults
(179). On the other hand, the phagocytic
and antitumor activities of newborn mouse
macrophages are higher than those of adult
mice (178).
The functional immaturity of leukocytes
is a significant factor in the human neonate's
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impaired host defenses (180). The neonate's
inflammatory response is insignificant com-
pared to that ofthe adult. This decrease in
inflammatory responsiveness in the neonate is
characterized by a higher proportion offunc-
tionally immature polymorphonuclear neu-
trophils (PMNs) and fewer monocytes during
the early hours ofinflammation compared to
infants 3-5 months ofage. During the early
period ofinflammation, a large number of
eosinophils are observed, which is unique to
this early period oflife (181). PMNs and
monocytes from neonates (i.e., cord blood)
are deficient in their chemotactic responses
compared to cells from adults (180,182).
Variable results have been obtained in studies
on the bactericidal activity of PMNs from
newborn humans, but in the absence of
unusual circumstances this activity appears to
be normal (180,182). After infection, the
pool of PMN and PMN precursors in the
newborn animal is rapidlydepleted compared
to adults (183). Furthermore, the number
and rate at which PMNs reach the site of
infection in newborn rats are decreased
compared to adults (184).
Complement components and activity
have been studied during fetal and neonatal
life in humans. The complement component
C3 appears in fetal tissues as early as 6 weeks
ofgestation, with C2 and C4 detected at 8
weeks ofgestation (185). The appearance of
complement in fetal tissue is due to synthesis
by the fetus because little or no transfer of
complement occurs across the placenta (186).
In general, it appears that many ofthe com-
ponents of complement, as well as the
hemolytic activity ofcomplement, are signifi-
cantly lower in newborns compared to adult
levels. Maturation ofcomponents ofthe das-
sical and alternative complement pathways
occurs in an age-related fashion, with C2, C4,
C5, C6, and B reaching adult levels by 6
months ofage (187). Although these quanti-
tative deficiencies are not necessarily associ-
ated with functional defects, the increase in
complement proteins during the first 6
months oflife may partially explain the age-
restricted susceptibility to bacterial infection
(188). In fact, evidence suggests that deficien-
cies in the opsonizing capacity ofcomple-
ment in neonatal serum may contribute to
this susceptibility (180). Work in fetal sheep
and pigs has demonstrated that whole com-
plement activity in serum is not detectable
until after day 123 ofgestation in the sheep
(normal gestation of 145 days) and that in
pigs the levels ofC8 and C9 are only 30% of
adultlevels at term (189).
The in vitro induction of interferon
production in lymphocytes obtained from
fetal (8-17 weeks ofgestation), newborn,
child (1 month to 10 years), and adult tissue
have been studied. The interferon titers were
in general the lowest among the fetal tissue
and the highest among newborns and chil-
dren. However, the data suggested that the
interferon-producing capacity ofhuman lym-
phocytes remains relatively constant through-
out intrauterine and postnatal life (186).
Gaps in Knowledge
There areseveral gaps in the present knowledge
base ofdrug- and chemical-induced develop-
mental immunotoxicity in humans and
animals. For example, although it is known
when certain structural components of the
immune system first appear and become
functional during development, comparative
information regarding the outcome ofexpo-
sure to chemical agents or mixtures ofchemi-
cals before, during, or shortly after any given
aspect of immune development is largely
unavailable. As a case in point, it is not
known ifexposure to TCDD before, during,
or after the establishment ofthe thymic rudi-
ment contributes most to the postnatal
immunosuppression caused by this chemical.
Such is true for essentially any immunotoxi-
cant one maywish to consider.
Continued animal studies remain the
most obvious way to define the most sensi-
tive periods ofimmune system development
to immunotoxicant exposure. In this regard,
although there are numerous studies in lab-
oratory rodents that have demonstrated the
sensitivity of immune system development
to perturbation by physical or chemical
insults, many ofthese studies used both pre-
and postnatal exposure regimens. Thus, it is
often unclear which portion of such expo-
sure contributes most to subsequent
immune impairment. A first step in making
this determination would involve cross-
fostering studies with known developmental
immunotoxicants to determine and com-
pare the effects of in utero versus lactational
and/or early postnatal exposure. In addi-
tion, the development and application of
more sensitive and predictive end points of
developmental immunotoxicity would facil-
itate the identification of critical windows
ofexposure.
Another gap in present knowledge is the
role that toxicokinetic and/or toxicodynamic
mechanisms play in age-dependent responses.
Specifically, it is uncertain ifthe inherent
increased susceptibility of the young
animal/human to immunotoxicants is due to
reduced ability to metabolize and/or excrete
the toxic moiety, or is more the result ofthe
exposure occurring during critical develop-
mental phases that require waves ofrapid cel-
lular proliferation and differentiation. Kinetic
studies and studies evaluating immunotoxi-
cant effects on the genes regulating cell cycle
and apoptosis in developing immune tissues
are needed to begin to answer these questions.
Information regarding possible conse-
quences ofexposure to immunotoxicants very
early in gestation (e.g., postconception/pre-
implantation) is also essentially unavailable.
For instance, it is presently not known ifcer-
tain chemical agents may affect hematopoi-
etic progenitor cells in the yolk sac before
migration to fetal liver, affecting immune
development. Similarly, no information is
available regarding possible adult exposures
(i.e., preconception) that mayhave the poten-
tial to alter the development of the fetal
immune system. The National Toxicology
Program (NTP) ofthe National Institute of
Environmental Health Sciences has, over the
past 15 years, developed a two-generation
study design (i.e., reproductive assessment by
continuous breeding) specifically aimed at
identifying potential hazards to male and/or
female reproductive performance resulting
from exposure to toxic chemicals (190). This
NTP paradigm for detecting reproductive
impairment in the offspring of rodents in
which the male and/or the female parent was
exposed to chemical agents before and/or
throughout the breeding and lactating period
could be directly applied to studying effects
of parental chemical exposure on immune
development ofthe offspring.
An additional recent area ofconcern in
developmental immunotoxicity is that early-
life exposure to certain chemical agents may
not only produce postnatal immunosuppres-
sion but also contribute to increased expres-
sion of hypersensitivity responses or
autoimmune diseases later in life. A careful
evaluation ofthis possibility that gestational
exposure to certain immunotoxicants may
relate to postnatal expression of aberrant
immune function is needed and represents a
major gap in our present understanding of
the possible consequences ofimmunotoxicant
exposure during development. Although
rodent studies will be critical to providing
data to fill this gap, recent success in organ
transplant procedures is resulting in a cohort
ofhumans who were exposed to therapeutic
immunosuppressive drugs from the precon-
ception period throughout gestation. These
individuals offer an unusual opportunity to
expand the human developmental immuno-
toxicity database, and should be carefully
followed inclinical andepidemiologicstudies.
Summary
Experimental studies suggest that the
production oflong-term secondary immuno-
deficiency in adult animals requires either
continued exposure to the inducing agent or
damage to primitive hematopoietic cells. In
contrast, low-level single-dose exposure to
certain immunotoxicants during immune
development may produce changes in the
immune system that are long-lasting or
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permanent, and that may be irreversible.
Thus, for at least some immunotoxic
assaults, it seems clear that the developing
immune system is highly sensitive relative to
adults, and, therefore, that developmental
immunotoxicant exposure should be limited
as much as possible.
It must further be emphasized that, to
date, postnatal immune end points evaluated
in experimental animals exposed during ges-
tation to immunotoxicants have focused
almost exclusively on inhibited immune func-
tion rather than on aberrant immune
responses. Clearly, the possibility that devel-
opmental exposure to immunotoxicants may
play a role in inducing or exacerbating hyper-
sensitivity or autoimmune responses needs to
be investigated in laboratory animal studies.
Further clinical and epidemiological studies
using large well-defined cohorts will also need
to be undertaken to establish whether acute
or chronic low-level exposure during prenatal
life contributes to human immunologic
dysfunction andsubsequent clinical disease.
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